Beam Therapeutics Receives U.S. FDA RMAT Designation for BEAM-302 to Treat Alpha-1 Antitrypsin Deficiency
Tuesday, May 13, 2025
Beam Therapeutics Inc., a biotechnology company focused on precision genetic medicine through base editing, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for BEAM-302. This investigational treatment is being developed for patients with alpha-1 antitrypsin deficiency (AATD), a genetic disorder that can affect the lungs and liver.
BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation containing a guide RNA and messenger RNA designed to correct the mutation responsible for severe AATD. The condition is caused by a mutation in the SERPINA1 gene, leading to reduced levels of functional alpha-1 antitrypsin (AAT) and harmful protein accumulation in the liver. It is estimated that around 100,000 people in the U.S. carry two copies of the faulty gene, although most cases remain undiagnosed.
The FDA’s RMAT designation is intended to support the development of regenerative therapies for serious or life-threatening conditions. It provides companies with enhanced regulatory support, including more frequent interactions with the agency and the possibility of faster review processes.
Earlier in March, Beam reported positive initial data from its Phase 1/2 clinical trial of BEAM-302. Results from the first three single-ascending dose groups showed the treatment was well tolerated and led to a dose-related increase in AAT protein levels. The highest dose tested so far (60 mg) achieved protein levels above the therapeutic threshold. The fourth group in the study, receiving a 75 mg dose, has now started, with updated results expected in the second half of 2025. The company also plans to begin treating patients with mild to moderate liver disease in Part B of the study later this year.
BEAM-302 targets the PiZ mutation (E342K), the most common cause of severe AATD. A single A-to-G base correction using Beam’s adenine base editor aims to reduce harmful protein buildup in the liver while restoring functional AAT in the blood. This approach may offer long-lasting benefits by addressing both lung and liver complications associated with AATD. Since the therapy works by correcting the gene at its original location, AAT levels are expected to rise naturally during inflammation or infection, which is not possible with current treatments.
At present, there are no approved curative treatments for AATD. The only available option in the U.S. is intravenous AAT protein replacement, which does not stop the decline in lung function. Beam aims to provide a one-time genetic solution to help patients manage both aspects of this progressive disease.
Source: globenewswire.com
